Delivery Order SPE2DB22D2103-SPE2DB24FR8KL
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $80,622.65 firm fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product, with a completion date of September 23, 2021. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp., the Corporate Office division of the pharmaceutical distribution company Cencora, Inc. The $7,618.08 firm fixed-price contract is for the supply of the medication Pulmozyme 1 mg/mL ampul 2.5 mL. This delivery order was placed under AmerisourceBergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract, valued at $13,490.07, is for the delivery of Pulmozyme, a 1 mg/ml medication for the treatment of cystic fibrosis, in 2.5 ml ampules. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $78,888.63 delivery order is for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml) under a Firm Fixed Price contract type. The award is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has a ceiling value of $20,964.92 and a completion date of May 27, 2022. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp is a...
- This federal contract award, valued at $13,994.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Pulmozyme 1 mg/ml ampules, a pharmaceutical product used in the treatment of cystic fibrosis. The award is a firm fixed-price delivery order with a completion date of September 22, 2021. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,564,053,701 units of Pulmozyme 1 mg/mL ampul 2.5mL. The contract has a Firm Fixed Price structure and a Ceiling Value of $12,494.73. It is not associated with a set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., also known as Amerisourcebergen. As a major supplier of pharmaceutical products and medical...
- This federal contract award, valued at $10,020.72, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, identified as SPE2DX15D3020|SPE2DX24FXKXU, is a delivery order valued at $10,809.18 for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract has a completion date of January 29, 2024 and is a firm fixed-price arrangement. This award is not designated as a set-aside contract. Amerisourcebergen Drug...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The contract is for the delivery of Pulmozyme, a medication used to treat cystic fibrosis, with a ceiling value of $75,527.66. The contract is a firm fixed-price arrangement and does not have a set-aside designation,...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB24FR8KLDelivery Order
This contract award, valued at $34,586.02, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a specialty pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, including the DLA and the Department of Justice Federal Bureau of Investigation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.6k | 10/16/23 |